 |
|
 |
|
|
|
 What is RSS?
Roche records $2.8bn loss in 2002
Roche has recorded a $2.8 billion net loss for 2002 after writing off CHF9 billion costs following its embarrassing exit from the vitamins market and heavy stock market losses...(more)
NHS diabetes czar appointed
Leading diabetes specialist Dr Sue Roberts has been appointed as the new National Clinical Director for Diabetes, and will oversee the development of the recently finalised national service framework...(more)
Bayer denies Lipobay cover-up
Bayer has refuted allegations that it concealed serious side-effects of its statin Lipobay before it was withdrawn in July 2001...(more)
Bidding war intensifies over Oxford GlycoSciences
A multi-million pound bidding war for Oxford GlycoSciences has broken out between UK biotech rivals Celltech and Cambridge Antibody Technology...(more)
EU regulator submits expansion plans
Medicines regulator the EMEA has asked the European Union for a subsidy increase of nearly 13% to pay for its expansion, including the induction of new EU member states...(more)
ClinPhone signals European expansion
UK clinical trials technology company ClinPhone is to develop its European business to serve clusters of pharmaceutical and biotech companies on the continent...(more)
Pfizer picks US research 'hotspot' for trials centre
Pfizer is to build a new $35 million clinical research centre in an R&D otspotin New Haven, Connecticut...(more)
Roche picks first Chugai drug
Roche has in-licensed the first medicine from Chugai since the companies merged their Japanese operations in October last year...(more)
Xenova cancer drug trial stopped
Shares in Xenova fell by 38% after independent safety experts suspended clinical trials of its lead product...(more)
GSK faces growing opposition to US parallel trade policy
GlaxoSmithKline is facing growing opposition from US patient groups and politicians to its attempt to block cheap drug imports from Canada...(more)
Make-or-break GP contract unveiled
GPs could see their pay rise by a third over the next three years if they accept the Government proposals to radically reform the services they provide...(more)
Milburn shortlists 50 hospitals for foundation status
Health Secretary Alan Milburn has shortlisted 50 hospitals he believes are ready to take on foundation status before the next election...(more)
Canada first market for Crestor
AstraZeneca Crestor is to receive an immediate launch in its first market after Canada regulator approved the new cholesterol lowering drug...(more)
£1m programme to improve epilepsy care
The Government is to spend an extra £1.2 million over the next two years to improve NHS services for people with epilepsy...(more)
NHS promotes primary care drug dictionary
A campaign to raise PCT awareness of the new Primary Care Drug Dictionary (PCCD) has been launched to promote its uptake among GPs and pharmacy IT system suppliers...(more)
AstraZeneca painkiller collaboration fails
The future of a potential new blockbuster pain killer under development by AstraZeneca is in doubt after it failed safety tests...(more)
Lilly and Sankyo to share sales team
Eli Lilly and Sankyo Pharma UK are to share sales representatives in an innovative new arrangement co-ordinated by contract sales company In2Focus...(more)
NICE launches intervention assessment programme
The safety and efficacy of new surgical and non-surgical interventions are to be assessed as part of a new NICE programme aimed at protecting patients and supporting NHS clinicians and organisations...(more)
ReNeuron in merger talks
ReNeuron, the UK biopharmaceutical company specialising in stem cells and neurological disorders, is in discussions with a potential merger partner...(more)
Celltech preparing bid for OGS
Celltech is set to make a bid for Oxford GlycoSciences to rival the £110 million all-share offer already tabled by Cambridge Antibody Technology...(more)
Three companies face US fraud lawsuits
Three pharmaceutical companies, GlaxoSmithKline, Pharmacia and Aventis, face legal action for alleged bribery and inflation of prescription drug prices in the US...(more)
Industry wins parallel import trademark case
A new UK High Court ruling has given pharma companies the right to block the sale of re-packaged parallel imports that infringe their copyright...(more)
MS risk-sharing scheme a 'waste of money'
The 'risk sharing' scheme to provide multiple sclerosis treatments is a waste of money and scientifically unsound, according to new report...(more)
Smaller hospitals win Government support
Smaller local hospitals are to become important centres for developing patient-centred care in a reversal of what the Government calls the iggest is bestapproach to NHS secondary care...(more)
GSK has 'turned corner', says Garnier
GlaxoSmithKline Chief Executive Jean-Pierre Garnier says he believes the company has urned a cornerin halting the decline in its R&D productivity, the chief underlying reason for its fall from favour among investors last year...(more)
AstraZeneca pins Crestor hopes on new data
AstraZeneca has submitted new data on its uperstatincholesterol-lowering drug Crestor to convince the US authorities of its safety profile...(more)
14 more PCTs to join pharmaceutical services revolution
Fourteen PCTs have been given the go-ahead to develop new and innovative services and improve patient services through community pharmacists...(more)
Iressa filed in Europe amid safety concerns
AstraZeneca has submitted its lung cancer drug Iressa for approval in Europe, despite concerns about side-effects...(more)
PowderJect splits chairman and chief executive roles
Pressure from shareholders has prompted UK vaccines group PowderJect to split the roles of chairman and chief executive...(more)
vCJD caution prompts Serono product withdrawal
Serono is to withdraw one of its hormone products from the UK after a case of variant Creutzfeldt-Jakob disease was confirmed in Italy, where the product is manufactured...(more)
J&J strengthens biotech business
Johnson & Johnson is to expand its biotech capabilities with a $2.4 billion purchase of US company Scios...(more)
Increased incentives for reporting prescription fraud
The Government has stepped up its fight against prescription fraud by increasing the reward for pharmacists identifying the crime, which costs the NHS £69 million every year...(more)
AstraZeneca files first for European bipolar disorder
AstraZeneca have filed the first European marketing application for an atypical antipsychotic as a treatment for manic episodes related to bipolar disorder...(more)
EU to conclude Pfizer-Pharmacia review in coming weeks
The European Commission has restarted its review of Pfizer merger with Pharmacia, and now expects to complete the investigation of the $60 billion deal by 27 February...(more)
New trial for treatment-resistant HIV
Boehringer Ingelheim has begun a global phase III trial for a new drug it hopes will be effective for HIV patients who have become resistant to current therapies...(more)
GSK puts new slant on Garnier pay battle
GlaxoSmithKline is to raise the issue of Chief Executive Jean-Pierre Garnier pay once again this week, saying it is intended as part of a wider increased remuneration package for 700 senior executives...(more)
Elan shows $2.4bn loss for 2002
Irish pharmaceutical company Elan made a larger than expected loss of $2.39 billion last year...(more)
Lilly's well-planned campaign launches 'spontaneity' ED drug
Eli Lilly have launched Cialis, the first serious rival to blockbuster erectile dysfunction drug Viagra amid a flurry of media coverage...(more)
Aventis cautious as growth slows
Aventis has reined in its 2003 forecasts and warned investors that the pace of its growth would slow to a igh single digitincrease...(more)
Pfizer rivals face uphill struggle
Pharmaceutical companies attempting to keep up with Pfizer industry lead have a battle on their hands, according to analysts Datamonitor...(more)
GSK productivity picking up
GlaxoSmithKline early-stage pipeline of new drugs has shown big improvements recently, according to analysts Deutsche Bank...(more)
Industry concern over EU reform
A serious lack of progress in EU moves to reform pharmaceutical regulation is now jeopardising key objectives, according to European industry body EFPIA...(more)
FDA to streamline approval process
The FDA has launched a programme to speed up approval of new drugs in response to growing concerns about lengthening review times and the scarcity of new drug launches...(more)
AstraZeneca sets aside $350m in fraud case
AstraZeneca has set aside $350 million to cover costs relating to its alleged defrauding of the US Medicare and Medicaid schemes...(more)
|
|
|
|
|
|
|
|
|
|
|
